 | ||||||
| Platform | |
Description | |
Value added | |
Future opportunities |
| ||||||
| Immediate release tablets with low solubility APIs |
Characterization of API and setting relevant particle size specification | Increase rate of solution and bioavailability | Low solubility API | |||
| ||||||
| Immediate release tablets with chemically unstable APIs |
Stabilizing with pH, antioxidants, novel/untraditional use of excipients and technologies | Stable product | Other products with unstable API | |||
| ||||||
| Immediate release tablets with Physically unstable APIs |
Methods to characterize hydrated and polymorphs. Using process technology and/or excipients to avoid conversion, own development of salt | Avoid patent litigations, exploit opportunities | All APIs with patented hydrates, solvates or polymorphs | |||
| ||||||
| Standard Immediate release, coated and uncoated |
Standard wet granulation or direct compression technologies, and optionally film coating | Broad portfolio | Any uncomplicated APIs | |||
| ||||||
| Creams ointments |
Broad portfolio | |||||
| ||||||
| Solutions |
Drops, oral solutions | Broad portfolio | ||||
| ||||||
| IV products |
Injectables, concentration for infusions, freeze dried products | Broad portfolio | ||||
| ||||||
TECHNOLOGY PLATFORMS 3/3
